U.S. pharma large copyright scrapped two experimental weight loss products final 12 months—a once-day-to-day pill, lotiglipron, as a consequence of elevated liver enzymes as well as a twice-everyday tablet, danuglipron, on account of sturdy side effects—but CEO Albert Bourla has said the company is set to “Enjoy and acquire” inside the bein